E
PLXP

Ergoteles’s PLx Pharma Inc. Common Stock PLXP Stock Holding History

Ergoteles’s Portfolio PLXP Stock Details PLXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-60,771
Closed -$9.97K – 1961
2022
Q4 		$9.97K Buy
+60,771
New +$25.4K ﹤0.01% 1371

Other funds holding PLXP

PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GSC
Ground Swell Capital Folly Beach, South Carolina $50.7M AUM 30.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return
SF
Synovus Financial Columbus, Georgia $8.74B AUM 12.78% 1-Year Est. Return

Ergoteles's PLXP Position: Q1 2023 in Review

Ergoteles sold out of PLx Pharma Inc. Common Stock (PLXP) in Q1 2023, closing a stake of 60,771 shares — an estimated $9.97K sold.

Ergoteles first reported a position in PLXP in Q4 2022 and held it in 1 quarter. The position peaked at $9.97K in Q4 2022. 34 funds tracked by Wall St. Rank hold PLXP as of Q1 2023.

  • Ergoteles reported no remaining PLx Pharma Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Ergoteles sold 60,771 PLx Pharma Inc. Common Stock shares in Q1 2023, an estimated $9.97K.
  • Ergoteles first reported a position in PLx Pharma Inc. Common Stock in Q4 2022 and held it in 1 quarter.
  • Ergoteles's PLx Pharma Inc. Common Stock position peaked at $9.97K in Q4 2022.
  • 34 funds tracked by Wall St. Rank held PLx Pharma Inc. Common Stock as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.